While no response was seen with sabatolimab in advanced solid tumor including melanoma, patients undergoing the treatment of sabatolimab plus PD-1 antibody exhibit better response signs like elevated expression of immune markers.641,642 LY3321367 has demonstrated promising antitumor activity in single use or in combination therapies with PD-L1 antibody for the treatment of advanced cancers, with 68.2% and 88.2% response rate, respectively (NCT03099109). The gene discussed is CD274; the disease is melanoma.